ArticleCNS neuroscience & therapeutics2025
The Association of Serum Biomarkers With Symptomatic Hemorrhagic Transformation in Acute Ischemic Stroke Patients: A Combined Retrospective and Prospective Study.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in genetics and multi-omics for ischemic stroke: from pathogenesis to clinical translation.Frontiers in genetics · 2026Review
- Association of Elevated Galectin-4 Concentrations with Obesity, Diabetes, and Cardiovascular Diseases.International journal of molecular sciences · 2025Review
- Predictive Value of the Modified Comprehensive Immunoinflammatory Indices for Hemorrhagic Transformation in Ischemic Stroke Patients Undergoing Thrombolysis: A Retrospective Study.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
background and purposeSymptomatic intracranial hemorrhage transformation (s-HT) is a serious complication of ischemic stroke, leading to early neurological deterioration and poor prognosis. It is an urgent problem to timely and effectively identify high-risk patients with s-HT at the early stage of stroke. However, so far, there are no effective clinical detection methods or measures. Therefore, the present study aimed to explore novel blood biomarkers related to s-HT.
methodsThis study includes two parts: a retrospective study and a prospective cohort study. In the first part, s-HT patients were screened (n = 18), and non-s-HTs (n = 128) were selected from the same period of case patients in the retrospective study cohort. The baseline blood samples were obtained within 30 min of admission, and the levels of 92 proteins related to cerebrovascular diseases were detected using the Olink proteomics technology. Multivariate logistic regression and receiver operating characteristic curves were used to analyze the relationship between serum biomarker levels and s-HT. In the second part, s-HT patients (n = 28) and non-s-HTs (n = 130) were selected from a prospective study cohort, which met the same criteria for inclusion and exclusion. Enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of potential biomarker(s) in serum screened from the first part to confirm its/their association(s) with s-HT.
resultsOlink assay showed that patients with s-HT had lower von Willebrand factor (vWF) levels and higher osteoprotegerin, phospholipase C, human insulin-like growth factor binding protein-7, matrix metalloproteinase-2, galectin-4, spondin-1 than non-s-HTs (n = 128) (p < 0.005) in a retrospective study cohort. Principal component (PC) and factor analysis showed that the seven biomarkers could explain 62.76% of the variance in the Olink biomarker set, and vWF was a main loading factor in PC2. Multivariate regression analysis showed that a low level of vWF was an independent risk factor (p < 0.05) for s-HT after adjusting for potential confounders. ELISA test results showed that s-HT patients had a significantly lower vWF levels than the non-s-HT group (26.57 [13.64-37.18] vs. 42.00 [26.02-55.52] ng/mL, p < 0.001) in the prospective study cohort. Incorporating vWF into the clinical risk factors significantly improved the accuracy of predicting s-HT (area under the curve [AUC, 0.731 vs. 0.641, p < 0.001], [AUC, 0.747 vs. 0.560, p < 0.001]) compared to a model employing only clinical risk factors in both study cohorts.
conclusionThrough the use of a combined retrospective and prospective study, vWF might be a novel blood biomarker for predicting s-HT occurrence in ischemic stroke patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.